CTOs on the Move

RareMed

www.raremed.com

 
RareMed Solutions offers comprehensive support services for specialty, orphan and ultra-orphan products. Our team has a breadth of experience developing and maintaining therapy specific solutions to ensure compliance. RareMed Solutions is the ideal partner for biotech firms and pharmaceutical manufacturers due to our custom solutions that are unique to each of our partner’s needs. RareMed Solutions is committed to providing the highest level of care to patients we serve. We offer specialized, highly-customizable services designed to increase patient access, affordability, and adherence to therapy. The extensive experience and unmatched service delivery translates to the best possible care for ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.raremed.com
  • 305 Merchant Lane
    Pittsburgh, PA USA 15205
  • Phone: 833.676.7273

Executives

Name Title Contact Details
Dennis Whalen
Vice President of Technology and Chief Technology Officer Profile

Similar Companies

Nidek

NIDEK offers a wide array of equipment designed for the diagnosis and treatment of retinal diseases, glaucoma, and other vision-impairing afflictions.

Cardiovascular Systems

Cardiovascular Systems, Inc. is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MyDental360

MyDental360 - Know what matters. Find what works. Powered by Kulzer The information you want on the subjects that affect your everyday work. We cover them from every angle—in a concise view delivered right to your inbox. Your Benefits • Busine...

Allergy Associates Research Center

Allergy Associates Research Center is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.